Hitoshi Ojima

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Hitoshi Ojima

Sep 3, 2024, 11:13 | Insight

Oxaliplatin with Fluoropyrimidine/Bevacizumab for Initial Therapy for Unresectable mCRC in Older Patients

Ramy Sedhom shared on X: A “RCT in Japan showing NO BENEFIT of adding OX…

Aug 31, 2024, 18:34 | Insight

Erman Akkus: First line treatment of metastatic Colorectal Cancer in older patients

Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X: “FOLFOX/Xelox…

Aug 31, 2024, 09:45 | Insight

Piotr Wysocki: Older patients with mCRC receiving fluoropyrimidine+bevacizumab do not gain additional benefit from adding oxaliplatin

Piotr Wysocki recently shared on LinkedIn: "A recent phase III clinical trial published in the…

All: 3 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023